Instrument Inactif

Autres langues Melinta Therapeutics, Inc.

Actions

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Melinta Therapeutics, LLC Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 Trial and Recently Approved Rezafungin CLSI Breakpoints for Candida Glabrata and Candida Auris	23/05
Venatorx Pharmaceuticals and Melinta Therapeutics Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam	23/02
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection	20/02
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id	05/12
Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO (Rezafungin for Injection)	02/10/23
Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens	10/07/23
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO (Rezafungin for Injection) for the Treatment of Candidemia and Invasive Candidiasis	22/03/23
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis	25/01/23
Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet	28/11/22
Melinta Therapeutics, Inc. Acquires U.S. Rights to TOPROL-XL® (Metoprolol Succinate) from New American Therapeutics, Inc	06/04/22
Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™	20/09/21
Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin)	07/07/21
Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy	06/07/21
Melinta Therapeutics, Inc. Announces Appointment of Susan Blum as Chief Financial Officer. Effective July 1, 2021	29/06/21
Melinta Therapeutics, LLC Appoints John Harlow as Chief Commercial Officer	29/03/21
Melinta Therapeutics, LLC Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections	15/03/21
Melinta Therapeutics, LLC Appoints Kristen Allgor as Chief Human Resources Officer	16/11/20
Melinta Therapeutics Announces Executive Changes	03/08/20
Melinta Therapeutics Announces CEO Changes	03/08/20
Melinta Therapeutics, Inc. cancelled the acquisition of Tetraphase Pharmaceuticals, Inc..	24/06/20

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Melinta Therapeutics, Inc.

Actions

Autres langues

Filtres